Log in

Relevant bibliographies by topics / Bendamustin

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Bendamustin'

Author: Grafiati

Published: 4 June 2021

Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bendamustin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bendamustin"

1

Schmale, Ine. "Langzeitergebnisse mit Bendamustin." Info Onkologie 19, no. 1 (February 2016): 60. http://dx.doi.org/10.1007/s15004-016-5242-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

red. "Neues Bendamustin-Generikum." Info Onkologie 19, no. 3 (April 2016): 50. http://dx.doi.org/10.1007/s15004-016-5315-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Berge, Doris. "Dreierkombination mit Bendamustin." Info Onkologie 15, no. 8 (December 2012): 50. http://dx.doi.org/10.1007/s15004-012-0471-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

red. "Neues Bendamustin-Generikum." Im Focus Onkologie 19, no. 3 (March 2016): 69. http://dx.doi.org/10.1007/s15015-016-2434-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

red. "Bendamustin in neuer Packung." Info Onkologie 18, no. 3 (April 2015): 50. http://dx.doi.org/10.1007/s15004-015-0837-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

ul. "Bendamustin in der Primärtherapie." best practice onkologie 8, no. 1 (February 2013): 31. http://dx.doi.org/10.1007/s11654-013-0031-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Reich, Bettina. "Multiples Myelom: Bendamustin als effektiver Partner für moderne Therapieregime." Onkologische Welt 03, no. 06 (2012): 259. http://dx.doi.org/10.1055/s-0038-1630274.

Full text

Abstract:

Bendamustin hat sich als Basismedikament zur Behandlung von niedrig malignen Lymphomen etabliert. Registerdaten aus dem hämato-onkologischen Alltag zeigen, dass Bendamustin heute in der Praxis bei indolenten Lymphomen und der chronischen lymphatischen Leukämie als häufigstes Zytostatikum eingesetzt wird (1).

APA, Harvard, Vancouver, ISO, and other styles

8

Werner, Walter, Michael Herold, Klaus Ruffert, Karlheinz Merkle, Axel Brakhage, Lorenzo Leoni, and Bruce D. Cheson. "Entwicklungsgeschichte: Bendamustin gestern, heute, morgen." Onkologie 36, s1 (2013): 2–10. http://dx.doi.org/10.1159/000346104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Arnheim, Katharina. "CLL: Ibrutinib schlägt Bendamustin/Rituximab." InFo Hämatologie + Onkologie 22, no. 1-2 (February 2019): 51. http://dx.doi.org/10.1007/s15004-019-6397-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

arn. "Bendamustin-Regime auf dem Prüfstand." Info Onkologie 15, no. 3 (April 2012): 50. http://dx.doi.org/10.1007/s15004-012-5049-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Bendamustin"

1

Pieper, Angelika. "Bendamustin, eine neue Substanz in der Therapie maligner Erkrankungen, insbesondere der Non-Hodgkin-Lymphome." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=974952559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rozanski, Marta. "Bendamustin in Kombination mit Thalidomid und Prednisolon (BPT) bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom: Ergebnisse einer Phase-I-Studie." Doctoral thesis, Universitätsbibliothek Leipzig, 2012. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-97058.

Full text

Abstract:

Thalidomid ist eine in der Therapie des fortgeschrittenen refraktären oder rezidivierten multiplen Myeloms (MM) wirksame Substanz, obwohl dosislimitierende Toxizitäten (DLT) ihren Einsatz beschränken können. In der vorliegenden Phase-I-Studie mit 28 Patienten mit rezidiviertem oder refraktärem MM nach konventioneller Chemotherapie oder Hochdosis (HD)-Chemotherapie mit Stammzelltransplantation (SCT) konnte gezeigt werden, dass eine Kombination von niedrig dosiertem Thalidomid mit Bendamustin und Prednisolon (BPT) die Wirksamkeit beibehält oder erhöht und gleichzeitig keine DLT auftritt. Die BPT-Therapie umfasste eine Dosis von Bendamustin (60mg/m2) Tag 1, 8 und 15 und Prednisolon (100mg) Tag 1, 8, 15 und 22, und eine eskalierende tägliche Dosis Thalidomid (50, 100, 200mg). Die Behandlungszyklen wurden alle 28 Tage bis zum Auftreten des maximalen Ansprechens, DLT oder Fortschreiten der Erkrankung wiederholt. 24 Patienten sprachen nach mindestens zwei Zyklen auf die Therapie an (vier komplette, sechs sehr gute partielle und 14 partielle Remissionen). Das mediane progressionsfreie Überleben und Gesamtüberleben für alle Patienten betrug 11 und 19 Monate. Nur leichte oder mittelschwere nicht-hämatologische Nebenwirkungen wurden beobachtet und kein Patient entwickelte dosislimitierende Hämatotoxizitäten. Die BPT-Therapie weist bei Patienten mit rezidiviertem oder refraktärem MM eine gute Verträglichkeit mit einem Ansprechen von über 80% auf. Die maximal tolerierte Dosis von Thalidomid wurde in dieser Studie nicht erreicht.

APA, Harvard, Vancouver, ISO, and other styles

3

Rozanski, Marta [Verfasser], Dietger [Akademischer Betreuer] Niederwieser, Wolfram [Akademischer Betreuer] Pönisch, and a. n. a. [Gutachter] n. "Bendamustin in Kombination mit Thalidomid und Prednisolon (BPT) bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom: Ergebnisse einer Phase-I-Studie : Bendamustin in Kombination mit Thalidomid und Prednisolon (BPT) bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom:Ergebnisse einer Phase-I-Studie / Marta Rozanski ; Gutachter: n.a. n.a. ; Dietger Niederwieser, Wolfram Pönisch." Leipzig : Universitätsbibliothek Leipzig, 2012. http://d-nb.info/1238151329/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tenzer, Aline [Verfasser]. "Zweitneoplasien, insbesondere hämatologische Neoplasien wie Myelodysplastisches Syndrom und Akute myeloische Leukämie, im Rahmen von Bendamustin-haltigen Therapien innerhalb der StiL-Studien / Aline Tenzer." Gießen : Universitätsbibliothek, 2013. http://d-nb.info/1065394950/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Roller, Fritz Christian [Verfasser]. "Bendamustin plus Rituximab versus CHOP plus Rituximab : Prospektiv randomisierte multizentrische Studie zur Therapieoptimierung (Primärtherapie) fortgeschrittener progredienter niedrigmaligner Non-Hodgkin-Lymphome und Mantelzell Lymphome / Fritz-Christian Roller." Gießen : Universitätsbibliothek, 2013. http://d-nb.info/1064991548/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Vereshchagina, Julia [Verfasser]. "Prospektiv randomisierte multizentrische Studie zur Therapieoptimierung von Rezidiven fortgeschrittener progredienter niedrigmaligner Non Hodgkin Lymphome und Mantelzell Lymphome : Bendamustin plus Rituximab versus Fludarabin plus Rituximab / Julia Vereshchagina." Gießen : Universitätsbibliothek, 2014. http://d-nb.info/1068535628/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Baradaran, Heravi Bita [Verfasser]. "Prospektiv randomisierte multizentrische Studie zur Therapieoptimierung (Primärtherapie) fortgeschrittener progredienter niedrigmaligner Non-Hodgkin-Lymphome (NHL7-Studie) mit der Entität Lymphoplasmozytisches Lymphom/ Morbus Waldenström : Bendamustin-Rituximab plus Nachbeobachtung oder 2 Jahre Rituximab-Erhaltungstherapie / Bita Baradaran Heravi." Gießen : Universitätsbibliothek, 2018. http://d-nb.info/1162054077/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bagnobianchi, A. "The molecular mechanism of action of Bendamustine." Thesis, University College London (University of London), 2015. http://discovery.ucl.ac.uk/1461456/.

Full text

Abstract:

Bendamustine has demonstrated clinical efficacy in the treatment of haematological malignancies and distinguish itself from other alkylating agents. The mechanistic and clinical differences associated with Bendamustine may be related to its structural features including a benzimidazole ring, although the mechanism of action is poorly understood. Understanding the molecular mechanism of Bendamustine could explain the therapeutic efficacy and identify potential biomarkers for response. The Bendamustine-DNA interaction in naked DNA, cytotoxicity, and ICL formation and repair (unhooking) in naked DNA or in cell lines and patient multiple myeloma cells by the single cell gel electrophoresis (comet) assay, were analyzed. DNA damage response (DDR) and potential mechanisms of acquired resistance to Bendamustine were also evaluated. Bendamustine alkylated DNA at guanine-N7 positions, produced ICLs in naked DNA and in cells, and demonstrated a cytotoxic effect comparable to conventional ICL drugs (Cisplatin, Melphalan). However, ICLs were not efficiently repaired (unhooked) in A549 cells, which could repair Cisplatin or Melphalan ICLs. In plasma cells from both Non-Melphalan Treated or Melphalan Treated patients, no evidence of efficient repair of Bendamustine ICLs was observed. Bendamustine DDR compared to Cisplatin or Melphalan gave a more selective pattern of expression of genes involved in DNA damage signaling pathways, cells defective in ERCC1, XPF, and homologous recombination repair showed less sensitivity to Bendamustine, there were differences in ɣH2AX and RAD51 foci formation and cell cycle distributions. In derived acquired resistant cell lines, resistance was associated with a reduced level of ICL at an equimolar drug dose compared to the parental lines. The molecular mechanism of Bendamustine is similar to conventional alkylating agents: DNA alkylation and ICL formation. However, ICL repair inefficiency and altered DDR are the differences between Bendamustine and conventional alkylating agents due to its benzimidazole ring that influences, showed by G1/S arrest of cell cycle population, its mechanism.

APA, Harvard, Vancouver, ISO, and other styles

9

Stokes, Jessica, Emely A. Hoffman, Yi Zeng, Nicolas Larmonier, and Emmanuel Katsanis. "Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation." WILEY-BLACKWELL, 2016. http://hdl.handle.net/10150/621784.

Full text

Abstract:

Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelo-suppressive than PT-CY, significantly increasing the number and proportion of CD11b(+)Gr-1(hi) cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T-and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.

APA, Harvard, Vancouver, ISO, and other styles

10

Huber, Stefan [Verfasser], and Armin [Akademischer Betreuer] Buschauer. "Investigations on bendamustine esters as new antitumor agents and the role of ABCG2 as a surrogate marker of breast cancer initiating cells / Stefan Huber. Betreuer: Armin Buschauer." Regensburg : Universitätsbibliothek Regensburg, 2015. http://d-nb.info/1092188045/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Bendamustin"

1

Blokdijk, G. J. Bendamustine Hydrochloride; Complete Self-Assessment Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Provan, Drew, Trevor Baglin, Inderjeet Dokal, and Johannes de Vos. Protocols and procedures. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0015.

Full text

Abstract:

Acute leukaemia: investigations - Platelet reactions and refractoriness - Prophylactic regimen for neutropenic patients - Guidelines for use of IV antibiotics in neutropenic patients - Treatment of neutropenic sepsis: source unknown - Treatment of neutropenic sepsis: source known/suspected - Prophylaxis for patients treated with purine analogues - Tumour lysis syndrome - Administration of chemotherapy - Antiemetics for chemotherapy - Intrathecal chemotherapy - Management of extravasation - Specific procedures after extravasation of cytotoxics commonly used in haematology - Anticoagulation therapy: heparin - Oral anticoagulation with VKA - Oral anticoagulation with NOAC - Management of needlestick injuries - Chemotherapy protocols - ABVD - BEACOPP/escalated BEACOPP - BEAM/LEAM - Bortezomib/dexamethasone - CHOP 21 and CHOP 14 - ChlVPP - CODOX-M/IVAC ± R - CTD and CTDa - DHAP ± R - ESHAP ± R - FC ± R - ICE ± R - Lenalidomide/dexamethasone - MPT - Mini-BEAM ± R - Nordic schedule (R-maxi-CHOP and R-high-dose cytarabine for MCL) - PMitCEBO - R-Bendamustine - R-CHOP - R-CVP and CVP - Rituximab: monotherapy and maintenance therapy - Stanford V

APA, Harvard, Vancouver, ISO, and other styles

3

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Mammit Kaur. Protocols and procedures. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199683307.003.0015_update_001.

Full text

Abstract:

Acute leukaemia: investigations - Platelet reactions and refractoriness - Prophylactic regimen for neutropenic patients - Guidelines for use of IV antibiotics in neutropenic patients - Treatment of neutropenic sepsis: source unknown - Treatment of neutropenic sepsis: source known/suspected - Prophylaxis for patients treated with purine analogues - Tumour lysis syndrome - Administration of chemotherapy - Antiemetics for chemotherapy - Intrathecal chemotherapy - Management of extravasation - Specific procedures after extravasation of cytotoxics commonly used in haematology - Anticoagulation therapy: heparin - Oral anticoagulation with VKA - Oral anticoagulation with NOAC - Management of needlestick injuries - Chemotherapy protocols - ABVD - BEACOPP/escalated BEACOPP - BEAM/LEAM - Bortezomib/dexamethasone - CHOP 21 and CHOP 14 - ChlVPP - CODOX-M/IVAC ± R - CTD and CTDa - DHAP ± R - ESHAP ± R - FC ± R - ICE ± R - Lenalidomide/dexamethasone - MPT - Mini-BEAM ± R - Nordic schedule (R-maxi-CHOP and R-high-dose cytarabine for MCL) - PMitCEBO - R-Bendamustine - R-CHOP - R-CVP and CVP - Rituximab: monotherapy and maintenance therapy - Stanford V

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bendamustin"

1

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Bendamustin." In Paravasation von Zytostatika, 73–75. Vienna: Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Horn, U., A. Härtl, J. Güttner, and H. Hoffmann. "Toxicity of the Alkylating Agent Bendamustin." In Archives of Toxicology, 504–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69928-3_120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Bendamustine." In Extravasation of Cytotoxic Agents, 66–68. Vienna: Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, and Sabine Wassertheurer. "Bendamustine." In Extravasation of Cytotoxic Agents, 118–21. Vienna: Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

"Bendamustin." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Stuttgart: Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ruffert, Klaus. "Cytostasan (Bendamustin) in der Therapie maligner Lymphome." In Contributions to Oncology, 256–66. S. Karger AG, 1999. http://dx.doi.org/10.1159/000425798.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Beljanski, Vladimir. "Bendamustine." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2010. http://dx.doi.org/10.1016/b978-008055232-3.64516-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"BENDAMUSTINE BENDROFLUMETHIAZIDE." In Litt's Drug Eruptions & Reactions Manual, 73. CRC Press, 2010. http://dx.doi.org/10.3109/9781841847665-26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

"Bendamustine Hydrochloride." In ASHP® Injectable Drug Information™, 191–92. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bendamustin"

1

Carniti, Cristiana, Silvia Gimondi, Antonio Vendramin, Sara Rizzitano, and Paolo Corradini. "Abstract 1693: The combination of romidepsin and bendamustin is synergistically cytotoxic and reverses the malignant phenotype in preclinical models of T-cell lymphoma." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1693.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kost, Sara E. F., Ali Saleh, Edgard M. Mejia, Marina Mostafizar, Eric D. J. Bouchard, Versha Banerji, Aaron J. Marshall, Spencer B. Gibson, Sachin Katyal, and James B. Johnston. "Abstract 1891: Cross-resistance and synergy between idelalisib and bendamustine in chronic lymphocytic leukemia." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1891.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Arimany-Nardi, Cristina, Arnau Montraveta, Eriong Lee-Vergés, Hermann Koepsell, Dolors Colomer, and Marçal Pastor-Anglada. "Abstract 885: Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine cytotoxic action." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-885.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Haskova, Zdenka, Margaret Whitacre, Kimberly Dede, Judithann M. Lee, Stephen H. Trulli, Marc Ciucci, John Toso, John White, and Zdenka L. Jonak. "Abstract LB-317: Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukemia." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bagnobianchi, Alessia, Victoria J. Spanswick, John P. Bingham, Konstantinos Kiakos, Paula Suarez-Henriques, Dean Smith, Kwee Yong, Daniel Hochhauser, and John A. Hartley. "Abstract 1766: Persistence of drug-induced DNA interstrand cross-links distinguishes bendamustine from conventional DNA cross-linking agents." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1766.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shah, Prexy, Kumudha Balakrishnan, William Wierda, and Varsha Gandhi. "Abstract 4530: Mechanism-based combination therapy of PI3 kinase delta-specific inhibitor Idelalisib with Bendamustine in chronic lymphocytic leukemia." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Beeharry, Neil, Corinne Stobbe, Mitchell R. Smith, and Timothy J. Yen. "Abstract 3664: Bendamustine induces a dose-dependent cell cycle arrest in Hela cells that results in different mitotic outcomes." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3664.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kost, Sara E. F., Eric D. J. Bouchard, William S. Liang, Versha Banerji, Spencer B. Gibson, Sachin Katyal, and James B. Johnston. "Abstract 2555: The mechanism of action of bendamustine alone or in combination with nucleoside analogs in chronic lymphocytic leukemia." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Amrein, Lilian, Anne-Laure Larocque, David Davidson, Lisa Peyrard, Daniel Borrelli, Bertrand Jean-Claude, and Lawrence Panasci. "Abstract 1881: New therapeutic options for CLL treatment: Src/c-abl-directed molecular re-engineering of chlorambucil and bendamustine." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1881.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Owonikoko, Taofeek Kunle, Guojing Zhang, Ping Yue, Suresh Ramalingam, Fadlo R. Khuri, and Shi-Yong Sun. "Abstract 3282: Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC)." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3282.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!